News Archive

2017

June

Media Release / Jun 23, 2017

NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

Read More
Media Release / Jun 23, 2017

Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

Read More
Media Release / Jun 23, 2017

Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®

Read More
Media Release / Jun 23, 2017

Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL

Read More
Media Release / Jun 23, 2017

Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)

Read More
Media Release / Jun 22, 2017

Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack

Read More
Media Release / Jun 21, 2017

Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance

Read More
Media Release / Jun 20, 2017

Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval

Read More
Media Release / Jun 20, 2017

Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden

Read More
Media Release / Jun 19, 2017

Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases

Read More

Pages

Related Links

Annual Report 2016

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More

Contact Media Relations

For media and journalist inquiries, please contact the Novartis Corporate Media Relations office by email or telephone.

Central Media Line:
Phone: +41 61 324 2200